poisar

Stock

BridgeBio Pharma, Inc. BBIO

$79.65-1.92%

Overview

BBIO market data

Price History

BBIO price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$3.79
Diluted earnings per share over the trailing twelve months.
Beta
0.95
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-124.4%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$46.81 – $93.42
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $15.8B · P/B 150.71 · P/S 27.31.

Company News

10 captured
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.The Motley Fool · Aug 14, 2026, 4:01 PM
BridgeBio Pharma Announces Pricing Of 5,000,000-Share Secondary Offering By Selling Stockholder KKR Genetic Disorder; Company Receives No ProceedsBenzinga · Aug 14, 2026, 11:31 AM
BridgeBio Pharma Launches Secondary Public Offering Of 5M Shares Of Common Stock By Selling Stockholder KKR Genetic Disorder L.PBenzinga · Aug 13, 2026, 9:46 PM
Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107Benzinga · Aug 12, 2026, 5:20 PM
Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106Benzinga · Aug 12, 2026, 3:42 PM
JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $111Benzinga · Aug 12, 2026, 2:00 PM
B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104Benzinga · Aug 11, 2026, 4:44 PM
TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $110Benzinga · Aug 11, 2026, 3:50 PM
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $97Benzinga · Aug 11, 2026, 3:45 PM
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $115Benzinga · Aug 11, 2026, 1:14 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock